natgillin/translations-raw huggingface dataset:
or a pharmaceutically acceptable form thereof. The compound according to claim 1, wherein the compound of Formula I is a compound selected from: 
Spoj iz zahtjeva 1, pri čemu je spoj: ili njegova farmaceutski prihvatljiva sol.
contacting a test compound with a host cell or with membrane of a host cell that expresses a G protein-coupled receptor, wherein the G protein-coupled receptor comprises an amino acid sequence selected from the group consisting of: amino acids 1-335 of SEQ ID NO:2; amino acids 2-335 of SEQ ID NO:2; 
(a) stavljanje u kontakt test spoja sa stanicom domačina ili membranom stanice domaćina koja izlučuje G protein-kupiran receptor pri čemu navedeni G protein kupirani receptor obuhvaća aminokiselinsku sekvencu izabranu iz skupine koju čine: (i) aminokiseline 1-3355 SEQ ID br. 2; (ii) aminokiseline 2-335 SEQ ID br. 2;
The composition of claim 1, wherein said composition is physically and chemically stable for at least 3 months. 
Sastav iz patentnog zahtjeva 1, pri čemu je navedeni sastav fizikalno i kemijski stabilan kroz najmanje 3 mjeseca.
a C3-12 carbon ring group and a heterocyclic group, wherein the heterocyclic group is a saturated or unsaturated ring group having, besides carbon atom, 1 to 4 hetero atoms selected from an oxygen atom, a nitrogen atom and a sulfur atom, each of the C1-4 alkyl groups of the above-mentioned 4), RA1, RA2, -RA3, RA4, RA5, RA6, R47, RA8 and RA9 is optionally substituted by the same or different 1 to 3 substituents selected from the following group C, and each of the C3-12 carbon ring groups of the above-mentioned 11) and RA7, and the heterocyclic groups of 12) and RA7 is optionally substituted by the same or different 1 to 5 substituents selected from the following group C group B is a group consisting of 
R je atom vodika, hidroksilna skupina, Ci alkilna skupina, C24 alkenilna skupina, gdje su Ci alkilna skupina i C24 alkenilna skupina izborno supstituirane s 1 do 3 supstituenta, koje se bira iz sljedeće skupine A, prstenasta skupina s C3_;> ugljika ili heterociklička skupina, gdje je heterociklička skupina zasićena ili nezasićena prstenasta skupina, koja uz atom ugljika sadrži 1 1 do 4 heteroatoma, koje se bira između atoma kisika, atoma dušika i atoma sumpora, gdje su prstenasta skupina s C3_,> ugljika 1 heterociklička skupina izborno supstituirane s 1 do 5 supstituenta, koje se bira iz sljedeće skupine B; gdje je skupina A skupina koju čine 1) atom halogena, 2) nitro skupina, 3) cijano skupina, 4) Cia alkilna skupina,
is selected from the group consisting of C1-4alkyl, cyclopropylmethyl, cyclobutylmethyl and [1-(trifluoromethyl)cyclopropyl]methyl, each of which is optionally substituted with one or more substituents as allowed by valence independently selected from the group consisting of F and hydroxy; 
je izabran iz grupe koja se sastoji od: C1-4alkil, ciklopropilmetil, ciklobutilmetil i [1-(trifluorometil) ciklopropil]metil, pri čemu je svaki izborno supstituiran sa jednim ili više supstituenata kao što je dozvoljeno valencijom nezavisno izabranim iz grupe koja se sastoji od: F i hidroksi;
deducing the presence or absence of methylation of the CpG dinucleotides amplified in step b) from the result of step b). 
Cc) dedukciju prisutnosti ili odsutnosti metilacije CpG dinukleotida amplificiranih u koraku b) iz rezulata koraka b).
In one aspect, the invention provides a compound of formula I: 
PATENTNI ZAHTJEVI Spoj formule I: z-(A)"
See Ausubel et al., Current Protocols in Molecular Biology, supra, Interscience, N.Y., §§6.3 and 6.4 (1987, 1992), and Sambrook et al., supra. Without limitation, examples of stringent conditions include washing conditions 12-20° C. below the calculated Tm of the hybrid under study in, e.g., 2×SSC and 0.5% SDS for 5 minutes, 2×SSC and 0.1% SDS for 15 minutes; 0.1×SSC and 0.5% SDS at 37° C. for 30-60 minutes and then, a 0.1×SSC and 0.5% SDS at 68° C. for 30-60 minutes. 
Vidi Ausubel i sur., Current Protocols in Molecular Biology, supra, Interscience, N, Y_., 886.3 1 6.4 (1987, 1992) i Sambrook i sur., supra, Primjeri strogih uvjeta uključuju, bez ograničenja, ispiranje na 12%20_C ispod izračunatog Tm hibrida kojeg se proučava u npr., 2 x SSc i 0.5% SDS 5 minuta, 2 x SSC i 0.1% SDS 15 minuta; 0.1 x SSC i 0.5% SDS pri 37 "€ 3060_ minuta i zatim, 0.1 x SSC i 0.5% SDS na 68 *C 3060_ minuta.
Use according to claim 1 or pharmaceutical composition for use according to claim 2, wherein said ionizing radiations are selected in the group consisting of X-Rays, Y-Rays, electron beams and radioisotope emissions. 
Uporaba u skladu s patentnim zahtjevom 1 ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 2, pri čemu su navedena ionizirajuća zračenja odabrana iz grupe koja se sastoji od X-zračenja, y-zračenja, elektronskih zraka i radioizotopnih emisija.
The reduction according to method 2 is performed by standard literature methods i.e. 
Redukcija u skladu s metodom 2 vrši se u skladu sa standardnim metodama opisanim u literaturi, npr.
a total amount of protein of at least 60% (w/w) on a dry weight basis, 
ukupnu količinu proteina od najmanje 60 % (tež./tež.) na osnovi suhe težine,
Toilet basket according to claim 9, wherein the containers are connected to one another via a non-water-conveying strut. 
WC košarica prema jednom od prethodnih zahtjeva, naznačena time da su u spremnicima (3a, 3b, 3c, 3d). pohranjeni pripravci koji se međusobno razlikuju.
decarboxylating the compound of Formula 15 or a salt thereof to yield the compound of Formula 9 or a salt thereof; and 
(b) dekarboksiliranju spoja Formule 7, ili njegove soli, kako bi se dobilo spoj Formule I, ili njegovu sol; i
The method according to claim 13, wherein nephropathy is diabetic nephropathy. 
Pripravak u skladu sa zahtjevom 13, naznačen time da nefropatija je dijabetička nefropatija.
These compositions can be reconstituted from lyophilised material. 
Ovi sastavi mogu biti rekonstituirani iz liofiliziranog materijala.
The antibody of claim 1, wherein the antibody inhibits Mac-1 binding to the fibrin or fibrinogen YC domain. 
Protutijelo 12 patentnog zahtjeva 1, pri čemu protutijelo inhibira vezanje Mac-1 za yC domenu fibrina 1li fibrinogena.
The sunscreen according to any of claims 30-45, furthermore comprising at least one pharmaceutically or cosmetically acceptable excipient or adjuvant. 
Pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što dodatno sadrži najmanje jedan farmaceutski ili kozmetički prihvatljivi vehikulum, i/ili najmanje jednu farmaceutski ili kozmetički prihvatljivu pomoćnu tvar ili adjuvans.
Generally, a daily dose for oral administration to an adult may be 0.01 to 1,000 mg (the weight of an active ingredient), and the dose may be administered once a day or several times a day as divided portions, or once in several days. 
Općenito, dnevna doza za oralnu primjenu na odrasloj osobi može biti 0,01 do 1,000 mg (težina aktivnog sastojka), a dozu se može primijeniti jednom dnevno ili nekoliko puta dnevno, kao podijeljene obroke, ili jednom u nekoliko dana.
in response to receiving the server command, preventing one or more other versions of the particular data object from the first child set of data from being sent to the base set of data by configuring the one or more servers to deny requests to send one or more other versions of the particular data object from the first child set of data; 
gdje je prva skupina verzija jednog ili više podatkovnih objekata spremljena u revizionirajućoj bazi podataka povezana s područjem baze u kojem su korisnici baze podataka objavili podatke, gdje je prva skupina verzija jednog ili više podatkovnih objekata povezana s područjem baze vidljiva korisnicima baze podataka;
A compound of claim 1 chosen from the following list: and 
Spoj iz patentnog zahtjeva 1 izabrano sa sljedeće liste: [image] [image] [image] [image]
A further specific embodiment of the process according to the present invention is characterized in that the redox cofactor(s) NAD+/NADH and/or NADP+/NADPH are regenerated by at least one further redox enzyme (reconverted into their original redox state). 
Postupak u skladu s patentnim zahtjevom 2, naznačen time, da se NAD + / NADH i NADP + / NADPH u topljivom obliku ili bilo u nepokretnom obliku na čvrstim tvarima koriste kao redoks kofaktor(i).
A compound as defined in any one of 1 to 12, or a pharmaceutically acceptable salt thereof, for use in the treatment of a disorder mediated by inappropriate PI3-kinase activity. 
Kombinacija u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačena time što je namijenjena upotrebi u liječenju poremećaja uzrokovanog neodgovarajućom aktivnošću PI3-kinaze.
%, more preferably, about 20 wt. 
%, povoljnije, oko 20 mas.
Meanwhile, the resulting treated ringed-mesh is subjected to a second process comprising the step of coating the ringed-mesh with at least one polymeric coating containing at least one other bioactive agent. 
što vlaknasta mrežica sadrži poliester, što matriks prstena sadrži najmanje jedno kontraceptivno sredstvo, te što polimerna obloga sadrži najmanje jedno od navedenih bioaktivnih sredstava.
The method according to claim 12 wherein the component d) is selected among C6-C9 alcohols. 
Metoda u skladu sa patentnim zahtjevom 12, naznačena time da je komponenta označena slovom d) odabrana između C6-C9 alkohola.
The composition of any one of claims 1 to 3, wherein the method of treating multiple sclerosis is selected from increasing walking speed, improving lower extremity muscle strength or improving lower extremity muscle tone, in a patient with multiple sclerosis. 
Sastav prema bilo kojem od zahtjeva 1 do 3, naznačen time da je postupak tretiranja multiple skleroze odabran od povećanja brzine hoda, poboljšanja mišićne snage donjih ekstremiteta ili poboljšanja mišićnog tonusa donjih ekstremiteta kod pacijenta s multiplom sklerozom.
A method for determining the species origin(s) of DNA in a food sample comprising conducting metagenomic sequence analysis of the food sample by high throughput sequencing to identify DNA from at least one species, wherein the metagenomic analysis comprises amplification and sequencing of a metagenomic target DNA sequence which is part of the myostatin (MSTN) gene, said metagenomic target DNA sequence being selected to allow for: i) co-amplification of the metagenomic target DNA sequence from a plurality of species using a set of conserved, common primers comprising primers comprising or consisting of the sequence of SEQ ID NO:1,SEQ ID NO:2, and SEQ ID NO:3; and ii) the identification of species origin of any amplified metagenomic target DNA on the basis of its sequence; wherein the method comprises the step of amplifying target DNA using a set of primers comprising or consisting of the sequence of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3. 
HR P20190055 T1 PATENTNI ZAHTJEVI Postupak utvrđivanja podrijetla vrsti od DNK u uzorku hrane sadržeći provođenje analize metagenomskih sekvenci uzorka hrane putem visokoprotočnog sekvenciranja zbog identifikacije DNK barem jedne vrste, naznačen time da metagenomska analiza sadrži amplifikaciju i sekvenciranje metagenomske ciljne DNK sekvence koja je dio miostatin (MSTN) gena, navedena metagenomska ciljna DNK sekvenca bivajući odabrana zbog omogućavanja: 1) koamplifikacije metagenomske ciljne DNK sekvence od pluraliteta vrsti koristeći set očuvanih, uobičajenih početnica, sadržeći ili sastojeći se od sekvence SEQ ID NO:1, SEQ ID NO:2, 1 SEQ ID NO:3; 1 11) identifikacije podrijetla vrste bilo koje amplificirane metagenomske ciljne DNK na osnovi svoje sekvence; naznačeno time da postupak sadrži korak amplifikacije ciljne DNK koristeći set početnica, sadržeći ili sastojeći se od sekvence SEQ ID NO: 1, SEQ ID NO:2, 1 SEQ ID NO:3.
Method for treating water at low cost, which will be used in industrial processes, that purifies the water and eliminates suspended solids in the water by filtering a small fraction of the total volume of water, the method comprising: 
Metoda za tretiranje vode niskih troškova te za korištenje nizvodno od industrijskog postupka (2), koja pročišćava vodu i uklanja otopljene čvrste čestice u vodi filtriranjem male frakcije ukupnog volumena vode, metoda obuhvaća:
In yet another aspect of the present invention, there are provided compounds of Formula I selected from the group consisting of: N-pyridin-2-yl-N′-3,5-dibromo-2-hydroxyphenylmethylene-hydrazine, N-pyridin-2-yl-N′-5-methyl-2-hydroxyphenylmethylene-hydrazine, N-pyridin-2-yl-N′-5-bromo-2-hydroxyphenylmethylene-hydrazine and N-pyridin-2-yl-N′-thiophen-2-ylmethylene-hydrazine. 
Spoj za uporabu sukladno patentnom zahtjevu 1, odabrano iz skupine sastavljene od N-piridin-2-yl-N'-3,5-dibromo-2-hidroksifenilmetilen-hidrazin, N-piridin-2-yl-N'-5-metil-2-hidroksifenilmetilen-hidrazin i (E)-2 ili njihove farmaceutski prihvatljive soli, estera ili solvata.
In other embodiments, the triacylglycerides-containing oils may include free fatty acids derived from at least one of camelina, carinata, cotton, jatropha, karanja, moringa, palm, castor, corn, linseed, peanut, soybean, sunflower, tung, babassu, or at least one of canola, shea butter, tall oil, tallow, waste vegetable oil, trap greases, used cooking oil, algal oil, and pongamia. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time, da ulje koje sadržava triacilgliceride sadržava slobodne masne kiseline dobivene od barem jednog od sljedećih: kamelija, karinata, pamuk, jatrofa, karanja, moringa, palma, ricinus, kukuruz, laneno sjeme, kikiriki, soja, suncokret, tung, babassu ili barem jedno od sljedećih: kanola, shea maslac, fall ulje, loj, otpadno biljno ulje, masti iz posuda za odvajanje, rabljeno ulje za kuhanje, ulje algi i pongamia.
The process of claim 18 wherein 1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid amide is prepared. The process of claim 18 further comprising the addition of an unsubstituted or a substituted 1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid amide, an excess amount of a suitable base, and a diaryidisulfide or a diheterocycledisulfide to a suitable solvent and heating to afford a compound of formula (I) wherein R1 is hydrogen. 
Postupak u skladu s patentnim zahtjevom 28, koji se dalje sastoji u koraku dodavanja nesupstituiranog ili supstituiranog amida 1H-pirolo[3,2-b]piridin-2-karboksilne kiseline, amida 1H-pirolo[3,2-c]piridin-2-karboksilne kiseline ili amida 1H-pirolo[2,3-c]piridin-2-karboksilne kiseline, suvišne količine pogodne baze, te diaril-disulfida ili diheterocikl-disulfida u pogodno otapalo, te grijanju kako bi se dobilo spoj formule (I), gdje R; je vodik.
In one aspect, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of an inflammatory disease which involves B cells. 
Spoj, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačen time što je upalna bolest i/ili alergijski poremećaj dermatitis.
In another embodiment, the invention contemplates polypeptide sequences having at least 90% or greater sequence homology to any one or more of the polypeptide sequences of antibody fragments, variable regions and CDRs set forth herein. 
nom HR P20191013 T1 protutijelo sadrži VL lanac 1 Vy lanac, redom, koji ima aminokiselinske sljedove koji k tome imaju najmanje 90% ili više homologije.
a light chain variable region, wherein the CDRL1 comprises the amino acid sequence of SEQ ID NO:3, the CDRL2 comprises the amino acid sequence of SEQ ID NO:21, the CDRL3 comprises the amino acid sequence of SEQ ID NO:29, and a heavy chain variable region wherein the CDRH1 comprises the amino acid sequence of SEQ ID NO:41, the CDRH2 comprises the amino acid sequence of SEQ ID NO:75, and the CDRH3 comprises the amino acid sequence of SEQ ID NO:89; 
varijabilnu regiju lakog lanca, pri čemu CDRL1 sadrži sekvencu aminokiselina SEQ ID NO:3, CDRL2 sadrži sekvencu aminokiselina SEQ ID NO:21, CDRL3 sadrži sekvencu aminokiselina SEQ ID NO:29, i varijabilnu regiju teškog lanca pri čemu CDRH1 sadrži sekvencu aminokiselina SEQ ID NO:41, CDRH2 sadrži sekvencu aminokiselina SEQ ID NO:75, i CDRH3 sadrži sekvencu aminokiselina SEQ ID NO:89; ili
A compound according to any one of claims 1 to 18 for use in inhibiting Aurora kinase activity in a cell or for use in treating an Aurora kinase-mediated disorder, for example wherein the Aurora kinase-mediated disorder is a cancer (such as colorectal cancer, ovarian cancer, breast cancer, gastric cancer, prostate cancer, and pancreatic cancer). 
Uporaba spoja prema patentnom zahtjevu 1 ili patentnom zahtjevu 2 u proizvodnji lijeka za liječenje poremećaja posredovanog preko Aurora kinaze koji je izabran iz grupe koju čine kancer, kolorektalni kancer, kancer jajnika, kancer dojke, kancer želuca, kancer prostate i kancer pankreasa.
Adenosine and its analogues induce "depressant-like" effects in animal models of psychiatric disorders (Minor et al., 1994, Behav Neurosci 108: 265-276; Woodson et al., 1998, Behav Neurosci 112: 399-409). 
Adenozin i njegovi analozi izazivaju učinak nalik smirivanju u životinjskim modelima koji simuliraju psihijatrijske poremećaje (Minor et al., 1994, Behav Neurosci 108: 265-276; Woodson et al., 1998, Behav Neurosci 112: 399-409).
placing (830)sodium bicarbonate in the pressure chamber; 
stavljanje natrijevog bikarbonata u komoru (21; 204; 304);
The method of claim 1, wherein the invasive procedure is a percutaneous coronary intervention. The method of claim 1, wherein the administration of cangrelor occurs within five days prior to the invasive procedure. A method of treating or inhibiting a disease or condition involving thrombosis in a subject in need of an invasive procedure who was previously treated with at least one thienopyridine, comprising administering to the subject an effective amount of cangrelor to at least partially inhibit platelet activities of the subject. 
Reverzibilni, kratko djelujući P2Y,> inhibitor za uporabu u postupku barem djelomične inhibicije aktivnosti trombocita kod subjekta koji je prethodno liječen s barem jednim tienopiridinom, pri čemu se liječenje s barem jednim tienopiridinom prekida prije davanja reverzibilnog, kratko djelujućeg inhibitora P2Y;,, naznačen time da reverzibilni, kratko djelujući inhibitor P2Y;> je cangrelor i daje se subjektu do 5 dana prije invazivnog postupka koji se provodi na subjektu ili tijekom invazivnog postupka koji se provodi na subjektu.
a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 2; or 
SEQ ID NO: 1 i varijabilno područje lakog lanca sadrži aminokiselinsku sekvencu od SEQ ID NO: 2.
An immunogenic composition comprising S. pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid which is pneumolysin, diphtheria toxoid or CRM197 and 19F is conjugated to a second bacterial toxoid which is diphtheria toxoid or CRM197 and further comprising conjugates of S. pneumoniae capsular saccharides 4, 6B, 9V, 14, 18C, 23F, 1, 5 and 7F, wherein the average size of the 19A saccharide is between 110 and 700 kDa. 
Imunogeni pripravak, naznačen time što sadrži konjugate saharida iz kapsule bakterije S. pneumoniae iz serotipova 19A i 19F, gdje je 19A konjugiran s prvim bakterijskim toksoidom, a 19F je konjugiran s drugim bakterijskim toksoidom, koji je difterijski toksoid ili CRM197, te što dodatno sadrži konjugate saharida 1, 4, 5, 6B, 7F, 9V, 14, 18C i 23F iz kapsule bakterije S. pneumoniae, gdje je prvi bakterijski toksoid različiti protein u odnosu na drugi bakterijski toksoid.
The process according to claim 3, wherein 2-5 equivalents of NaO(t-Bu), 2-5 equivalents piperazine, 0.2-0.6 mole-% Pddba2, and 0.6-1 mole-% rac-BINAP are dispersed in toluene to obtain mixture A', to which mixture approximately 1 equivalent 2-bromo-iodobezene is added to obtain mixture B', to which mixture 1 equivalent 2,4-dimenthylthiophenol is added and the resulting mixture is heated to reflux for 3-7 hours to obtain 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine. 
Postupak prema zahtjevu 14, gdje se 2-5 ekvivalenata NaO(t-Bu), 2-5 ekvivalenata piperazina, 0.2-0.6 mol% Pddba2 i 0.6-1 mol-% rac-BINAP dispergiraju u toluenu da se dobije smjesa A’, u tu smjesu se dodaje oko 1 ekvivalent 2-bromo-jodobenzola da se dobije smesa B’, u tu smjesu se dodaje 1 ekvivalent 2,4-dimetiltiofenola i finalna se smjesa zagrijava do refluksa 3-7 sati da se dobije 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]-piperazin.
o is an integer from 0 to 3 inclusive; and p is 1. 
o je cijeli broj od 0 do 4 uključivo; i p je cijeli broj od 0 do 5 uključivo;
The antibody or a functional fragment of the antibody according to claim 18, wherein the first and the second heavy chain are each independently selected from items (ii) or (iii), and wherein the amino acid residue located at the carboxyl terminus of the heavy chain is amidated, preferably wherein the amino acid residue is a proline residue. 
Antitijelo ili funkcionalni fragment antitijela prema patentnom zahtjevu 18, gdje prvi i drugi teški lanac su svaki nezavisno odabrani od stavki (11) ili (111), 1 gdje aminokiselinski ostatak lociran na karboksil terminusu teškog lanca je amidiran, poželjno gdje je aminokiselinski ostatak prolinski ostatak.
The polypeptide or polynucleotide of claim 1, further comprising administering one or more agents that enhance autophagy of the a-synuclein complexes or enhance degradation of a-synuclein complexes within lysosomes. 
Primjena patentnog zahtjeva 1, koja dalje sadrži administraciju jednog ili više agenasa koji pojačavaju autofagiju a-sinukleinskih kompleksa, ili polipeptid koji pojačava process razlaganja a-sinukleinskih kompleksa unutar lizozoma.
The blood brain barrier shuttle of claims 4 - 6, wherein the effector entity is a full length antibody directed to AB. 
Prijenosnik za krvno-moždanu barijeru prema zahtjevima od 4 do 6, naznačen time, da entitet efektora je protutijelo pune duljine usmjereno na Af.
is a hydrogen atom, methyl, methoxy, or a halogen atom; 
R' je atom vodika, metil, metoksi, ili atom halogena;
The reaction mixture was cooled and the solvent removed by evaporation. 
Reakcijska smjesa se ohladi i otapalo se ukloni isparavanjem.
The method of claim 3, wherein said cutting and forming is performed in at least two dimensions around said bar stock. 
Postupak sukladno zahtjevu 2, pri čemu, je rezanje i formiranje izvedeno u barem dvije dimenzije oko materijala.
A method for detecting that a flush valve (10) should be replaced, the method comprising: 
Sustav za detektiranje da ventilni element (300) treba zamijeniti, gdje sustav sadrži:
The synthetic approach for preparing para-phenyl alkynyl benzaldehydes is well known. 
Sintetski je pristup pripravi para-fenil alkanil benzaldehida dobro poznat.
The process of claim 1 wherein the reacting step is carried out in a solvent selected from the group consisting of acetonitrile, nitromethane, halogenated hydrocarbons and mixtures thereof. 
Postupak iz patentnog zahtjeva 1, naznačen time da je reakcija provedena u otapalu koje je odabrano iz sljedeće skupine: acetonitril, nitrometan, halogenirani ugljikovodici i njihova smjesa.
Alternatively, the Hib conjugate is present in a lower saccharide dose than the saccharide dose of each of the at least two N. meningitidis polysaccharide conjugates. 
Imunogeni pripravak u skladu s patentnim zahtjevom 1, naznačen time što konjugat Hib je prisutan u manjoj dozi saharida od doze saharida za svaki od najmanje dva dodatna konjugata bakterijskih saharida.